Effectiveness and tolerability of Pegilated interferon alfa 2a and Ribavirin therapy at patient with chronic hepatitis C

Written by Török Imola, Băţaga Simona, Georgescu Dan, Bratu Ana, Farkas Szabolcs

The aim of this study was to assess early (EVR) and sustained virological response (SVR) and the presents of side effects. 51 patients with chronic hepatitis C, under therapy with Peginterferon alfa 2a and Ribavirin were followed-up. Monthlly was followed-up the complete blood count, liver biochemistry level and the presents of another of side effects. HCV-RNA level was tested at 12 weeks of therapy (EVR) and at 24 weeks after the finishing of therapy (SVR). From 51 patients 74,5% have EVR and 39,2% have SVR. Severe anemia was found at 1 patient, severe neutropenia at 2 patients and severe thrombocytopenia at 4 patients. From the wellknowed side effects of the combinated therapy, most frequent was found arthralgia, myalgia, pyrexia, fatigue, headache, weight loss, dry cough, depression, skin rush. One of three patient, who received Peginterferon alfa 2a and Ribavirin had sustained virological response. The side effects were frequently present but at many cases these are transitory and well tolerated.

Print   Email